CN1679800A - Medicine for treating oral exulceratio and periodontal turgescene, and preparation thereof - Google Patents
Medicine for treating oral exulceratio and periodontal turgescene, and preparation thereof Download PDFInfo
- Publication number
- CN1679800A CN1679800A CN 200510032791 CN200510032791A CN1679800A CN 1679800 A CN1679800 A CN 1679800A CN 200510032791 CN200510032791 CN 200510032791 CN 200510032791 A CN200510032791 A CN 200510032791A CN 1679800 A CN1679800 A CN 1679800A
- Authority
- CN
- China
- Prior art keywords
- medicine
- present
- ethanol
- propolis
- abelmoschi manihot
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A Chinese medicine in the form of gel for treating oral ulcer and periodontitis is proportionally prepared from sunset abelmoschus flower, bee gelatine and additive. Its preparing process is also disclosed.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of oral ulcer and periodontal turgescene and preparation method thereof, belong to the field of Chinese medicines.
Background technology
Oral diseases such as oral ulcer are difficult disease, and sickness rate is more and more higher, and modern medicine lacks effective treatment means at present.It is main clinical manifestation that primary disease forms pain caused with stomatocace, and having in disease damage part in early days feels nervous sends out puckery, scorching hot or mild pain; Occur scorching hot sample during ulcer and have an intense pain, symptom aggravation during feed.Weight person's ulcer number is many, and area is big, and pain is more violent, with sialorrhea, babble, feed difficulty, also diseases such as heating, headache, pharyngalgia, xerostomia, insomnia, constipation can occur.
Toothache is meant and the pain that gingiva causes because of certain reason is one of modal symptom in the oral disease that there are the appearance of this disease in the dental caries in the modern medicine, pulpitis, apicitis, periodontitis and dentin hypersensitiveness etc. more.
Above-mentioned two cards, though sick different, because of consistent, be the disease that excess-fire is a trouble, control method, when being usefulness with heat clearing away, antiinflammatory, pain relieving.
Summary of the invention
The purpose of this invention is to provide a kind of treatment oral ulcer safe, effective, easy to use and the medicine of periodontal turgescene.
Another object of the present invention has provided the preparation method of this Chinese medicine composition.
Medicament selection Flos abelmoschi manihot of the present invention be because the Flos abelmoschi manihot analgesic activity less than morphine greater than aspirin.More outstanding is, the mechanism of action in its only road is different from morphine class, aspirin class analgesic, but calcium channel blocker with by stoping human calcium's ion to enter in the neurocyte, reaches analgesic activity.Effects such as remarkable pain relieving, antiinflammatory are arranged.Select for use propolis to be because propolis can suppress and kill bacteria, obvious antiinflammatory, pain relieving, itching-relieving action are arranged, ulcer is had healing effect preferably.
The proportioning of medicine of the present invention is: the propolis that contains the Flos abelmoschi manihot and 1%～99% (weight) of 99%～1% (weight).
The best proportioning of medicine of the present invention is: the propolis that contains the Flos abelmoschi manihot and 5.7% (weight) of 94.3% (weight).
The preparation method of above-mentioned each component being made medicine of the present invention is:
A) get Flos abelmoschi manihot, add 10%～90% ethanol extraction repeatedly, each 0.5～4 hour, merge extractive liquid, reclaimed ethanol, and being concentrated into does not have the alcohol flavor, adds boiling water extraction repeatedly, filters, and filtrate is packed in the macroporous adsorptive resins;
B) with 10%～90% ethanol elution, collect eluent, reclaim ethanol, concentrate;
C) add silica gel, mix thoroughly, drying adds aqueous organic solvent, soaks repeatedly, and merging filtrate reclaims solvent, and drying gets the Flos abelmoschi manihot extract powder;
D) get propolis, be ground into coarse powder, add 10%～90% ethanol extraction repeatedly, each 0.5～4 hour, merging filtrate reclaimed ethanol, concentrated, and drying gets the propolis extract powder;
E) Flos abelmoschi manihot extract powder, propolis extract powder add an amount of adjuvant that can form gel, adopt the preparation method of pharmaceutics to make gel.
Gel is an aqueous gel.
The specific embodiment
Below routine by experiment beneficial effect of further setting forth medicine of the present invention, these experimental examples comprise the pharmacodynamic experiment and the clinical observation on the therapeutic effect experiment of medicine of the present invention.
The clinical observation of [experimental example 1] Drug therapy oral ulcer of the present invention and periodontal turgescene:
Experiment material:
1, is subjected to the reagent thing
Medicine of the present invention.Usage: skin, mucosa delivery.
2, animal and antibacterial
Animal: Kunming mouse (20 ± 2g), the Wistar rat (200 ± 20g), Cavia porcellus (200 ± 20g), be the SPF level, the male and female dual-purpose.Rabbit body weight 2 ± 0.2kg, the male and female dual-purpose.
Pathogenic microorganism: staphylococcus aureus, staphylococcus epidermidis, bacillus pyocyaneus, escherichia coli, Candida albicans are clinical strain.
Experimental technique
The function of medicine cures mainly according to the present invention, according to the requirement of relevant pharmacodynamics in the new drug preclinical study guideline, has carried out following observation index:
1. antibacterial action: external inhibitory action to staphylococcus aureus, staphylococcus epidermidis, bacillus pyocyaneus, escherichia coli, Candida albicans.
2. antiinflammatory action: on Carrageenan causes rat paw edema, to Oleum Tiglii induced mice auricle edema, to the swollen influence that forms of rat granuloma.
3. antiulcer action: the influence of bacterial canker, scald property and the acetic acid oral ulcer that the rabbit staphylococcus epidermidis is caused.
4. anti-allergic effects: to the influence of guinea pig skin pruritus due to the histamine.
5. analgesic activity: to the influence of mice thermic pain.
Experimental result
1, antibacterial action
Medicine of the present invention is 1: 160 at external minimum inhibitory concentration to staphylococcus aureus (MIC), be 1: 80 to the staphylococcic minimum inhibitory concentration of epidermis, to the oidiomycetic minimum inhibitory concentration of white is 1: 10, bacillus pyocyaneus and escherichia coli are not had the obvious suppression effect, the results are shown in Table 1～5.
Table 1 medicine of the present invention is to aureus with inhibition
| Drug level | Medicine of the present invention | Blank bacterial strain 1 | ||||
| Bacterial strain 1 | Bacterial strain 2 | Bacterial strain 3 | Bacterial strain 4 | Bacterial strain 5 | ||
| ????1∶10 ? ????1∶20 ? ????1∶40 ????1∶80 ? ????1∶160 ? ????1∶320 ????1∶640 | ??- ? ??- ? ??- ??- ? ??- ? ??- ??+ | ????- ? ????- ? ????- ????- ? ????- ? ????+ ????+ | ????- ? ????- ? ????- ????- ? ????- ? ????- ????+ | ????- ? ????- ? ????- ????- ? ????- ? ????- ????+ | ????- ? ????- ? ????- ????- ? ????- ? ????+ ????+ | ????+ ? ????+ ? ????+ ????+ ? ????+ ? ????+ ????+ |
"-" expression asepsis growth, "+" expression have bacteria growing (down together)
Table 2 medicine of the present invention is to the staphylococcic inhibitory action of epidermis
| Drug level | Medicine of the present invention | Blank bacterial strain 1 | ||||
| Bacterial strain 1 | Bacterial strain 2 | Bacterial strain 3 | Bacterial strain 4 | Bacterial strain 5 | ||
| ????1∶10 ????1∶20 ????1∶40 ????1∶80 ????1∶160 ????1∶320 ????1∶640 | ????- ????- ????- ????- ????- ????- ????+ | ????- ????- ????- ????- ????+ ????+ ????+ | ????- ????- ????- ????- ????- ????- ????+ | ????- ????- ????- ????- ????- ????+ ????+ | ????- ????- ????- ????- ????+ ????+ ????+ | ????+ ????+ ????+ ????+ ????+ ????+ ????+ |
Table 3 medicine of the present invention is to the oidiomycetic inhibitory action of white
| Drug level | Medicine of the present invention | Blank bacterial strain 1 | ||||
| Bacterial strain 1 | Bacterial strain 2 | Bacterial strain 3 | Bacterial strain 4 | Bacterial strain 5 | ||
| ????1∶10 ????1∶20 ????1∶40 ????1∶80 ????1∶160 ????1∶320 ????1∶640 | ????- ????+ ????+ ????+ ????+ ????+ ????+ | ????- ????- ????+ ????+ ????+ ????+ ????+ | ????- ????- ????+ ????+ ????+ ????+ ????+ | ????- ????+ ????+ ????+ ????+ ????+ ????+ | ????- ????- ????+ ????+ ????+ ????+ ????+ | ????+ ????+ ????+ ????+ ????+ ????+ ????+ |
Table 4 medicine of the present invention is to the inhibitory action of bacillus pyocyaneus
| Drug level | Medicine of the present invention | Blank bacterial strain 1 | ||||
| Bacterial strain 1 | Bacterial strain 2 | Bacterial strain 3 | Bacterial strain 4 | Bacterial strain 5 | ||
| ????1∶10 ????1∶20 ????1∶40 ????1∶80 ????1∶160 ????1∶320 ????1∶640 | ??+ ??+ ??+ ??+ ??+ ??+ ??+ | + + + + + + + | ?+ ?+ ?+ ?+ ?+ ?+ ?+ | + + + + + + + | + + + + + + + | ??+ ??+ ??+ ??+ ??+ ??+ ??+ |
Table 5 medicine of the present invention is to colibacillary inhibitory action
| Drug level | Medicine of the present invention | Blank bacterial strain 1 | ||||
| Bacterial strain 1 | Bacterial strain 2 | Bacterial strain 3 | Bacterial strain 4 | Bacterial strain 5 | ||
| ????1∶10 ????1∶20 ????1∶40 ????1∶80 ????1∶160 ????1∶320 ????1∶640 | ???+ ???+ ???+ ???+ ???+ ???+ ???+ | ?+ ?+ ?+ ?+ ?+ ?+ ?+ | ?+ ?+ ?+ ?+ ?+ ?+ ?+ | ?+ ?+ ?+ ?+ ?+ ?+ ?+ | + + + + + + + | ??+ ??+ ??+ ??+ ??+ ??+ ??+ |
2, antiinflammatory action
The result shows that medicine of the present invention causes rat paw edema and the swollen hypertrophy of rat granuloma is all had the obvious suppression effect Oleum Tiglii induced mice auricle edema, on Carrageenan.The results are shown in Table 6～8.
Table 6 medicine of the present invention to the inhibitory action of Oleum Tiglii induced mice auricle edema (x ± s, n=12)
| Group | Dosage (g/kg) | Swelling degree (mg) | Inhibitory rate of intumesce (%) |
| Dosage medicine low dose of the present invention in the heavy dose of medicine of the present invention of blank metronidazole medicine of the present invention | ? ????0.0064 ????3.2 ????1.6 ????0.8 | ????20.75±4.63 ????11.25±5.46 **????6.25±5.14 **????8.17±4.02 **????11.75±4.77 ** | ? ????45.78 ????69.88 ????60.64 ????43.37 |
Compare with the blank group:
*P＜0.05,
*P＜0.01.
Table 7 medicine on Carrageenan of the present invention cause rat paw edema inhibitory action (x ± s, n=10)
| Group | Dosage (g/kg) | Cause scorching back different time swelling degree (mm) | |||
| ??2h | ??4h | ??6h | 10h | ||
| Dosage medicine low dose of the present invention in the heavy dose of medicine of the present invention of blank metronidazole medicine of the present invention | ? ??0.0064 ??3.2 ??1.6 ??0.8 | ??4.5±1.4 ??5.0±1.2 ??4.2±1.3 ??4.4±1.3 ??5.3±1.6 | ??7.2±1.2 ??6.4±2.0 ??4.2±0.9 **??4.9±1.8 **??6.9±0.7 | ??5.2±1.5 ??4.3±1.3 **??3.7±0.7 **??4.1±1.1 *??5.0±0.9 * | 2.2±1.2 2.2±1.1 2.3±1.5 2.4±1.3 2.8±1.5 |
Compare with the blank group:
*P＜0.05,
*P＜0.01
Table 8 medicine of the present invention to the swollen outgrowth influence of rat granuloma (x ± s, n=20)
| Group | Dosage (g/kg) | Granuloma net weight (mg) | Suppression ratio (%) |
| Dosage medicine Low-dose dexamethasone of the present invention fluocinolone acetonide in the heavy dose of medicine of the present invention of blank metronidazole medicine of the present invention | ? ??0.0064 ??3.2 ??1.6 ??0.8 ??0.005 ??0.8 | ??84.60±23.76 ??83.95±19.15 ??70.65±15.29 *??80.25±16.71 ??83.25±17.78 ??67.00±11.84 **??71.20±15.41 * | ??- ??0.77 ??16.49 ??5.14 ??1.60 ??20.80 ??15.84 |
Compare with the blank group:
*P＜0.05,
*P＜0.01.
3, anti-oral ulcer effect
The result shows that medicine of the present invention can obviously promote the healing of scald property, acetic acid, bacillary oral ulcer, the results are shown in Table 9, table 10, table 11.
Table 9 medicine of the present invention to rabbit scald the property oral ulcer inhibitory action (x ± s, n=10)
| Group dosage (g/kg) | Ulcer area (mm) | |||
| Before the medication | 3d behind the medicine | 6d behind the medicine | 9d behind the medicine | |
| The blank metronidazole, (0.0016) KUIYANG SAN, (0.8) medicine heavy dose of the present invention, (0.8) dosage in the medicine of the present invention, (0.4) medicine low dose of the present invention, (0.2) | ??5.75±1.00 ??6.07±0.91 ??6.12±0.71 ??6.07±1.07 ??5.89±1.16 ??5.90±0.66 | ??5.28±0.92 △??4.52±1.87 △??4.62±1.76 △??3.85±2.18 *△△??4.20±1.88 △??4.50±1.84 △ | ??2.37±1.24 △△??1.31±0.86 *△△??1.27±0.6O *△△??0.65±0.56 **△△??1.14±0.71 **△△??1.58±0.62 *△△ | ??0.45±0.24 △△??0.38±0.19 *△△??0.32±0.28 *△△??0.20±0.03 **△△??0.34±0.31 *△△??0.41±0.15 *△△ |
Compare with the blank group:
*P＜0.05,
*P＜0.01; With before self medication relatively,
△P＜0.05,
△ △P＜0.01.
Table 10 medicine of the present invention to the inhibitory action of rabbit acetic acid oral ulcer (x ± s, n=10)
| Group dosage (g/kg) | Ulcer area (mm) | ||||
| Before the medication | 3d behind the medicine | 6d behind the medicine | 9d behind the medicine | 12d behind the medicine | |
| The blank metronidazole, (0.16) KUIYANG SAN, (0.8) medicine heavy dose of the present invention, (0.8) dosage in the medicine of the present invention, (0.4) medicine low dose of the present invention, (0.2) | ??5.06±1.32 ??5.10±1.31 ??4.98±1.33 ??5.15±1.36 ??5.11±0.90 ??5.06±1.25 | 4.30±0.37 3.69±1.04 △3.59±0.73 *△3.83±0.61 *△4.11±1.00 4.2O±1.12 | 4.19±0.88 △3.16±1.22 *△△2.90±1.25 *△2.35±0.92 **△△2.54±0.78 **△ν3.60±0.40 *△△ | ??2.76±1.38 △△??1.60±1.12 *△△??1.37±1.16 *△△??1.15±0.82 **△△??1.52±0.57 **△△??1.74±0.94 *△△ | ??1.49±0.83 △△??0.84±0.42 *△△??0.81±0.47 *△△??0.41±0.24 **△??0.74±0.20 **△??0.83±0.52 *△△ |
Compare with the blank group:
*P＜0.05,
*P＜0.01; With before self medication relatively,
△P＜0.05,
△ △P＜0.01.
Table 11 medicine of the present invention to the inhibitory action of the bacillary oral ulcer of rabbit (x ± s, n=10)
| Group dosage (g/kg) | Ulcer area (mm) | ||||
| Before the medication | 2d behind the medicine | 4d behind the medicine | 6d behind the medicine | 9d behind the medicine | |
| The blank metronidazole, (0.16) KUIYANG SAN, (0.8) medicine heavy dose of the present invention, (0.8) dosage in the medicine of the present invention, (0.4) medicine low dose of the present invention, (0.2) | ??8.11±0.75 ??8.22±1.15 ??7.96±0.74 ??8.10±0.82 ??8.21±1.07 ??8.06±1.28 | 7.99±0.79 △△7.28±0.63 *△△7.33±0.72 *△△6.43±0.56 *△△7.11±1.20 *△△7.50±1.25 △△ | 7.43±0.612 △△6.73±0.57 *△△6.61±0.62 *△△3.75±0.53 **△△5.02±0.92 **△△6.37±1.13 *△△ | 6.01±0.66 △△3.99±0.65 **△△5.32±0.56 *△△2.35±0.49 **△△3.62±076 **△4.40±0.93 **△△ | 2.12±0.37 △△1.40±0.95 *△△1.35±0.75 *△△0.52±0.26 **△△0.82±0.37 **△△1.46±0?77 *△△ |
Compare with the blank group:
*P＜0.05,
*P＜0.01; With before self medication relatively,
△P＜0.05,
△ △P＜0.01.
4, itching-relieving action
The result shows, medicine of the present invention has the obvious suppression effect to guinea pig skin pruritus due to the histamine, the results are shown in Table 12.
Table 12 medicine of the present invention to Guinea Pig Histamine cause the inhibitory action of itching (x ± s, n=10)
| Group | Dosage (g/kg) | Itch-threshold (the histamine total amount, ug) | Itch-threshold raising rate (%) |
| Dosage medicine low dose of the present invention in the heavy dose of medicine of the present invention of blank metronidazole fluocinonide medicine of the present invention | ? ??0.0064 ??0.8 ??3.2 ??1.6 ??0.8 | ????42.00±48.43 ????45.00±55.10 ????254.5±300.98 **????469.0±366.32 **????132.54±98.62 *????52.00±50.24 | ????- ????7.14 ????505.95 ????1016.67 ????277.51 ????23.81 |
Compare with the blank group:
*P＜0.05,
*P＜0.01.
5, to thermic influence bitterly
Medicine of the present invention has the obvious suppression effect bitterly to the mice thermic, the results are shown in Table 13.
The influence that table 13 medicine of the present invention reacts bitterly to the mice thermic (x ± s, n=10)
| Group dosage (g/kg) | Pain threshold after the administration (s) | |||
| 30min after the medication | 60min after the medication | 90min after the medication | 120min after the medication | |
| Dosage (1.6) medicine low dose of the present invention (0.8) in blank morphine (0.01) metronidazole (0.0064) Sucralfate (1.6) medicine heavy dose of the present invention (3.2) medicine of the present invention | ??10.60±3.78 ??36.40±6.87 **??11.10±8.13 ??30.90±18.06 **??21.70±7.80 **??18.50±7.38 **??18.60±7.92 ** | 18.80±5.55 45.40±11.11 **13.20±4.66 31.20±16.76 *32.20±12.33 **27.10±9.68 *24.40±12.89 | ??19.80±14.64 ??37.22±10.74 **??14.90±11.27 ??30.30±21.08 ??32.10±10.38 *??35.30±15.65 *??28.60±16.55 | ?24.30±16.33 ?38.10±11.86 ?16.30±10.30 ?33.10±20.36 ?28.50±13.79 ?29.90±17.62 ?36.50±18.63 |
Compare with the blank group:
*P＜0.05,
*P＜0.01.
Experimental result shows, medicine of the present invention has stronger inhibitory action external to staphylococcus aureus, staphylococcus epidermidis, Candida albicans, and Oleum Tiglii induced mice auricle inflammation there is obvious inhibitory action, on Carrageenan causes rat paw edema and the granuloma induced by implantation of cotton pellets hypertrophy also has certain inhibitory action, shows that it has significantly antiinflammatory action.Also promote the healing of chemical, scald property and bacillary oral ulcer significantly.In addition, skin pruritus due to the histamine and thermic pain also there is obvious inhibitory action.
The capsule preparation of [embodiment 1] medicine of the present invention
A) get Flos abelmoschi manihot, add 80% alcohol heating reflux and extract 2 times, each 2 hours, merge extractive liquid, reclaimed ethanol, and being concentrated into does not have the alcohol flavor, adds boiling water extraction 2 times, filtered while hot, and filtrate is packed in the macroporous adsorptive resins;
B) wash with water earlier, abandon water liquid, 15 times of amounts of reuse, 80% ethanol elution is collected eluent, decompression recycling ethanol, and being concentrated into relative density is 1.05;
C) add silica gel, mix thoroughly, drying under reduced pressure is weighed, and adds 10 times of amount ethyl acetate: ethanol: water, its ratio are to make solvent at 82.6: 8.4: 9, soak 3 times, and each 6 hours, merging filtrate reclaimed solvent, and drying under reduced pressure must the Flos abelmoschi manihot extract powder;
D) get propolis, be ground into coarse powder, add 8 times of amount 70% ethanol, 30 ℃ of warm macerating extract 3 times, and each 2 hours, merging filtrate reclaimed ethanol, concentrated, and drying under reduced pressure gets the propolis extract powder;
E) get Flos abelmoschi manihot extract powder, propolis extract powder, add the appropriate amount of auxiliary materials mixing, the snap fit capsule of packing into.
The granule preparation of [embodiment 2] medicine of the present invention
A) get Flos abelmoschi manihot, add 80% alcohol heating reflux and extract 2 times, each 2 hours, merge extractive liquid, reclaimed ethanol, and being concentrated into does not have the alcohol flavor, adds boiling water extraction 2 times, filtered while hot, and filtrate is packed in the macroporous adsorptive resins;
B) wash with water earlier, abandon water liquid, 15 times of amounts of reuse, 80% ethanol elution is collected eluent, decompression recycling ethanol, and being concentrated into relative density is 1.05;
C) add silica gel, mix thoroughly, drying under reduced pressure is weighed, and adds 10 times of amount ethyl acetate: ethanol: water, its ratio are to make solvent at 82.6: 8.4: 9, soak 3 times, and each 6 hours, merging filtrate reclaimed solvent, and drying under reduced pressure must the Flos abelmoschi manihot extract powder;
D) get propolis, be ground into coarse powder, add 8 times of amount 70% ethanol, 30 ℃ of warm macerating extract 3 times, and each 2 hours, merging filtrate reclaimed ethanol, concentrated, and drying under reduced pressure gets the propolis extract powder;
E) get Flos abelmoschi manihot extract powder, propolis extract powder, add the appropriate amount of auxiliary materials mixing, granulate, drying is made granule.
The preparation tablets of [embodiment 3] medicine of the present invention
A) get Flos abelmoschi manihot, add 80% alcohol heating reflux and extract 2 times, each 2 hours, merge extractive liquid, reclaimed ethanol, and being concentrated into does not have the alcohol flavor, adds boiling water extraction 2 times, filtered while hot, and filtrate is packed in the macroporous adsorptive resins;
B) wash with water earlier, abandon water liquid, 15 times of amounts of reuse, 80% ethanol elution is collected eluent, decompression recycling ethanol, and being concentrated into relative density is 1.05;
C) add silica gel, mix thoroughly, drying under reduced pressure is weighed, and adds 10 times of amount ethyl acetate: ethanol: water, its ratio are to make solvent at 82.6: 8.4: 9, soak 3 times, and each 6 hours, merging filtrate reclaimed solvent, and drying under reduced pressure must the Flos abelmoschi manihot extract powder;
D) get propolis, be ground into coarse powder, add 8 times of amount 70% ethanol, 30 ℃ of warm macerating extract 3 times, and each 2 hours, merging filtrate reclaimed ethanol, concentrated, and drying under reduced pressure gets the propolis extract powder;
E) get Flos abelmoschi manihot extract powder, propolis extract powder, add the appropriate amount of auxiliary materials mixing, granulate, drying, compacting is made tablet in flakes.
The above only is the preferred embodiment of patent of the present invention, and all equalizations of being done according to patent claimed range of the present invention change and modify, and all should belong to the covering scope of Patent right requirement of the present invention.
Claims (4)
1. medicine for the treatment of oral ulcer and periodontal turgescene, it is characterized in that: described medicine contains the propolis of the Flos abelmoschi manihot and 1%～99% (weight) of 99%～1% (weight).
2. according to the medicine of described treatment oral ulcer of claim 1 and periodontal turgescene, it is characterized in that: described medicine contains the propolis of the Flos abelmoschi manihot and 5.7% (weight) of 94.3% (weight).
3. according to the preparation method of described treatment oral ulcer of claim 1 and periodontal turgescene medicine, it is characterized in that it comprises the steps:
A) get Flos abelmoschi manihot, add 10%～90% ethanol extraction repeatedly, each 0.5～4 hour, merge extractive liquid, reclaimed ethanol, and being concentrated into does not have the alcohol flavor, adds boiling water extraction repeatedly, filters, and filtrate is packed in the macroporous adsorptive resins;
B) with 10%～90% ethanol elution, collect eluent, reclaim ethanol, concentrate;
C) add silica gel, mix thoroughly, drying adds aqueous organic solvent, soaks repeatedly, and merging filtrate reclaims solvent, and drying gets the Flos abelmoschi manihot extract powder;
D) get propolis, be ground into coarse powder, add 10～90% ethanol extractions repeatedly, each 0.5～4 hour, merging filtrate reclaimed ethanol, concentrated, and drying gets the propolis extract powder;
E) Flos abelmoschi manihot extract powder, propolis extract powder add an amount of adjuvant that can form gel, adopt the preparation method of pharmaceutics to make gel.
4. according to the preparation method of described treatment oral ulcer of claim 3 and periodontal turgescene medicine, it is characterized in that: gel is an aqueous gel.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100327917A CN100518749C (en) | 2005-01-19 | 2005-01-19 | Medicine for treating oral exulceratio and periodontal turgescene, and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100327917A CN100518749C (en) | 2005-01-19 | 2005-01-19 | Medicine for treating oral exulceratio and periodontal turgescene, and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1679800A true CN1679800A (en) | 2005-10-12 |
| CN100518749C CN100518749C (en) | 2009-07-29 |
Family
ID=35066806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100327917A Expired - Fee Related CN100518749C (en) | 2005-01-19 | 2005-01-19 | Medicine for treating oral exulceratio and periodontal turgescene, and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100518749C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106420506A (en) * | 2016-12-02 | 2017-02-22 | 成都大学 | Sunset abelmoschus root-olive toothpaste and preparation method thereof |
| CN109953930A (en) * | 2017-12-14 | 2019-07-02 | 江苏苏中药业集团股份有限公司 | A kind of Chinese herbal toothpaste and preparation method thereof with canker sore repair |
-
2005
- 2005-01-19 CN CNB2005100327917A patent/CN100518749C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106420506A (en) * | 2016-12-02 | 2017-02-22 | 成都大学 | Sunset abelmoschus root-olive toothpaste and preparation method thereof |
| CN109953930A (en) * | 2017-12-14 | 2019-07-02 | 江苏苏中药业集团股份有限公司 | A kind of Chinese herbal toothpaste and preparation method thereof with canker sore repair |
| CN109953930B (en) * | 2017-12-14 | 2022-04-12 | 苏中药业集团股份有限公司 | Chinese herbal medicine toothpaste with dental ulcer repairing effect and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100518749C (en) | 2009-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1883618A (en) | Effective parts of cirald daphne bark, preparation method and application thereof | |
| CN1895487A (en) | Externally-applied Chinese medicine and its preparation | |
| CN1382478A (en) | Extract of mulberry twig and its extracting process and novel usage | |
| CN1044445C (en) | Tibetan preparatory medicine and preparation method thereof | |
| CN1806821A (en) | Rhinitis-treating medicine | |
| CN1680355A (en) | Preparation of suaveolic flavone for treating chronic pharyngitis and chronic tonsilltiis | |
| CN1312095A (en) | Hypertension-treating medicine | |
| CN1679800A (en) | Medicine for treating oral exulceratio and periodontal turgescene, and preparation thereof | |
| CN101049337A (en) | Medication for curing furuncle, sore, and carbuncle, and preparation method | |
| CN1300175C (en) | Medicinal polysaccharide component of spinulate hedgehog fungus, its prepn and medicinal composition | |
| CN1191848C (en) | Chinese medicine prepn for treating throat diseases and stomatopathy and its prepn process | |
| CN100467037C (en) | Medicine for treating hypertension and its preparing process | |
| CN100335044C (en) | Rhinitis treating soft medicinal capsule and preparation process thereof | |
| CN1817350A (en) | Silkworm sand total alkaloid and preparation thereof | |
| CN100335090C (en) | Medicinal composition for tonifying kidney and eliminating obstruction, and its preparing method | |
| CN1686414A (en) | Wound dispelling swell dispersing tincture and its preparation method | |
| CN101077349A (en) | Total alkaloids of subprostrate sophora root soft capsules and preparation method and application thereof | |
| CN1557824A (en) | Silkworm excrement total alkaloid and its preparation method | |
| CN1457809A (en) | Dandelion preparation and preparing method | |
| CN1323704C (en) | Chinese medicine composition for treating prostatitis and prostatic hyperplasia and its preparing method | |
| CN1879740A (en) | Compound Chinese medicinal preparation for treating acne and preparation method thereof | |
| CN1737007A (en) | Gastrodine derivative, its preparation method, pharmaceutical composition and uses | |
| CN1660349A (en) | Combination of medication by using beartyberry and dragon's blood resin as combination of activities | |
| CN1923230A (en) | Medicine for treating rheumatism and rheumatoid disease, and its preparation method | |
| CN1562145A (en) | Guangsheng hemp extract, its preparing method and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090729 Termination date: 20220119 |